KORU Medical Systems Inc. (KRMD) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.05 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 50%. A quarter ago, it was expected that this company would post a loss of $0.04 per share when it actually produced a loss of $0.02, delivering a surprise of 50%.Over the last four quarters, the company has surp ...

KORU Medical Systems Q1 2024 Earnings Call May 1, 2024 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 or [_] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________. Commission File Number: 0-12305 KORU MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 13-304488 ...

EXHIBIT 99.1 KORU MEDICAL SYSTEMS, INC. ANNOUNCES 2024 FIRST QUARTER FINANCIAL RESULTS DELIVERING DOUBLE-DIGIT REVENUE GROWTH MAHWAH, NJ – May 1, 2024 – KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient- centric large volume subcutaneous infusion solutions, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights ● First ...

KORU Medical Systems, Inc. (NASDAQ:KRMD) Q4 2023 Earnings Conference Call March 13, 2024 4:30 PM ET Company Participants Louisa Smith - Gilmartin Group Linda Tharby - President and CEO Tom Adams - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Alex Nowak - Craig-Hallum Capital Caitlin Cronin - Canaccord Genuity Jason Bednar - Piper Sandler Operator Good day and welcome to the KORU Medical Systems Fourth Quarter and Full Year 2023 Earnings Call. All participants will be in listen only ...

贷款条款 - 贷款和担保协议签订日期为2024年3月8日[1] - 变更控制是指任何时候，任何“人”或“团体”成为或获得成为借款人的普通投票权的30.0%或更多的“受益所有者”[9] - 法律变更是指本协议签订日期后发生的任何法律、规则、法规或条约的采纳或生效[10] - 抵押品是指在附件A中描述的借款方的所有财产、权利和资产[10] - 当前负债是指借款人及其子公司对银行的所有债务和责任，再加上借款人及其子公司在一年内到期的总负债的总额[13] - 循环额度到期日为2025年12月31日[38] 资金和账户 - 可用金额是指可循环信贷额度或借款基础的较小值，减去所有未偿还的资金[3] - 现金等价物包括美国政府或其机构发行或无条件担保的到期日不超过一年的有市场流通的直接债务[8] - "Deposit Account" 是指根据法典定义的任何“存款账户”，并可能随后对该术语进行的补充[14] - "Designated Deposit Account" 是指以美元计价，账号为*********，由借款人与银行附属机构保持的账户[14] - "Dollars"、“dollars”或使用符号“$”仅指美国合法货币，而不是任何其他货币，无论该货币是否使用“$”符号表示其货币或是否可以轻松转换为美国合法货币[14] - "Dollar Equivalent" 是指在任何时间点，(a)关于以美元计价的任何金额，以及(b)关于以外币计价的任何金额，根据银行在纽约市的当时汇率确定的等值美元金额[14] 合规要求 - Healthcare Permit是指与借款人业务相关的卫生法律规定下发放或要求的许可证[26] - HIPAA是指1996年卫生保险便携性和责任法案，由2009年卫生信息技术促进经济和临床健康法案修订[26] - 美国内部税收法典是指1986年修订的美国内部税收法典[28] - 每个贷款方和其子公司都是根据其组织法律合法存在并有效[61] - 每个贷款方有权将其声称拥有的知识产权转让给银行[62] - 每个贷款方及其各自子公司均按时提交了所有必需的税务申报和报告，并及时支付了所有应付的外国、联邦、州和地方税款[64] - 贷款方不知道有任何对其或其各自子公司之前税务年度提出的索赔或调整，可能导致额外的税款超过10万美元[64] - 贷款方和其各自子公司已按照其条款支付了所有必要的养老金、利润分享和递延薪酬计划的金额[64] - 贷款方应将信贷延期的款项仅用于营运资金和其他一般公司用途，而不用于个人、家庭、农业用途[64] - 贷款方相信其及其子公司所保有的保险足够，并符合在相同或类似业务中运营的公司的惯例[64] - 贷款方及其各自子公司没有违反任何适用的反贿赂法律，包括但不限于英国贿赂法和美国《1977年外国腐败行为法》[65] - 贷款方及其各自子公司在所有重要方面遵守所有适用的医疗法律[66] - 每个贷款方应确保其及其各自子公司遵守其所在司法管辖区的所有法律、法规和条例[68] - 每个贷款方应获得所有必要的政府批准，以履行其在贷款文件中的义务并向银行提供抵押品的担保权[68] - 贷款方及其各自子公司的运营和财产应在所有重要方面遵守所有适用的医疗法律，包括HIPAA[68] 还款条款 - 借款人应按照协议规定的利率偿还贷款本金和利息[50] - 如果贷款被加速偿还，借款人应立即支付所有未偿还的本金和利息，以及其他应付款项[50] - 借款人有权提前偿还贷款，但必须提前通知银行并支付所有未偿还的本金和利息[50] - 超出总额的部分需立即支付给银行，同时支付利息[50] - 利率根据Prime Rate的变化进行调整，每月支付[52] - 借款人需支付一次性的承诺费用、提前还款费用、终止费用、未使用的信贷额度费用和银行费用[52] - 借款人应在到期日前支付所有应付款项，否则银行有权从借款人的存款账户中扣款[53]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to __________ Commission file number 0-12305 KORU MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 13-3044880 (State or other ...

KORU Medical Systems, Inc. (NASDAQ:KRMD) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Linda Tharby - Chief Executive Officer and President, Director Tom Adams - Chief Medical Officer Conference Call Participants Caitlin Cronin - Canaccord Genuity Joseph Downing - Piper Sandler Frank Takkinen - Lake Street Capital Operator Good day. And welcome to the KORU Medical Systems Third Quarter 2023 Earnings Call. All participants will be in listen-only mode. [Operator Instruction ...

KORU Medical Systems Q3 2023 Earnings Call November 8, 2023 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 or [_] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________. Commission File Number: 0-12305 KORU MEDICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 13-30 ...